First-line sunitinib cost-effective alternative to interferon-α in renal cancer

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 561, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Erlotinib marginally cost effective for NSCLC

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 601, 2010-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer

By Lo Peter C.   Dahlberg Suzanne E.   Nishino Mizuki   Johnson Bruce E.   Sequist Lecia V.   Jackman David M.   Jänne Pasi A.   Oxnard Geoffrey R.  

Cancer, Vol. 121, Iss. 15, 2015-08 ,pp. : 2570-2577

Blackwell Publishing

Access to resources Recommend Favorite

The Cost Effectiveness of ACE Inhibitors as First-Line Antihypertensive Therapy

By Nordmann A.J.   Krahn M.   Logan A.G.   Naglie G.   Detsky A.S.  

PharmacoEconomics, Vol. 21, Iss. 8, 2003-01 ,pp. : 573-585

Adis International

Access to resources Recommend Favorite

A Cost-Effectiveness Analysis of First-Line Controller Therapies for Persistent Asthma

By Ya-Chen Tina Shih  

PharmacoEconomics, Vol. 25, Iss. 7, 2007-01 ,pp. : 577-590

Adis International

Access to resources Recommend Favorite